{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:11:36Z","timestamp":1780567896688,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01-AI090935-01"],"award-info":[{"award-number":["P01-AI090935-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jtbi.2015.08.032","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T06:01:31Z","timestamp":1442383291000},"page":"89-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins"],"prefix":"10.1016","volume":"386","author":[{"given":"Gajendra W.","family":"Suryawanshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"August (33)","key":"10.1016\/j.jtbi.2015.08.032_bib1","doi-asserted-by":"crossref","first-page":"34083","DOI":"10.1074\/jbc.C400235200","article-title":"APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein","volume":"279","author":"Alce","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtbi.2015.08.032_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/msb.2010.4","article-title":"Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy","volume":"6","author":"Althaus","year":"2010","journal-title":"Mol. Syst. Biol."},{"issue":"15","key":"10.1016\/j.jtbi.2015.08.032_bib3","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/JVI.01799-08","article-title":"Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling","volume":"83","author":"Althaus","year":"2009","journal-title":"J. Virol."},{"issue":"January (1)","key":"10.1016\/j.jtbi.2015.08.032_bib4","doi-asserted-by":"crossref","first-page":"e1004609","DOI":"10.1371\/journal.ppat.1004609","article-title":"Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1","volume":"11","author":"Apolonia","year":"2015","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"issue":"5684","key":"10.1016\/j.jtbi.2015.08.032_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1126\/science.1100658","article-title":"APOBEC-mediated editing of viral RNA","volume":"305","author":"Bishop","year":"2004","journal-title":"Science"},{"issue":"5865","key":"10.1016\/j.jtbi.2015.08.032_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1152725","article-title":"Identification of host proteins required for HIV infection through a functional genomic screen","volume":"319","author":"Brass","year":"2008","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jtbi.2015.08.032_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","article-title":"Analysis of combined drug effects","volume":"4","author":"Chou","year":"1983","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.jtbi.2015.08.032_bib10","doi-asserted-by":"crossref","first-page":"e1002931","DOI":"10.1371\/journal.ppat.1002931","article-title":"Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities","volume":"8","author":"Cocka","year":"2012","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.jtbi.2015.08.032_bib11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.cub.2003.10.034","article-title":"The Vif protein of HIV triggers degradation of the human antiretroviral dna deaminase apobec3g","volume":"13","author":"Conticello","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jtbi.2015.08.032_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/135965350400900216","article-title":"Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy","volume":"9","author":"Dixit","year":"2004","journal-title":"Antivir. Ther."},{"issue":"12","key":"10.1016\/j.jtbi.2015.08.032_bib13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/j.1600-0854.2011.01277.x","article-title":"HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface","volume":"12","author":"Dube","year":"2011","journal-title":"Traffic"},{"issue":"January (3)","key":"10.1016\/j.jtbi.2015.08.032_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jmb.2004.10.067","article-title":"APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles","volume":"345","author":"Dussart","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.jtbi.2015.08.032_bib15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.2735","article-title":"HIV-AIDS","volume":"14","author":"Fauci","year":"2013","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jtbi.2004.04.015","article-title":"Optimizing within-host viral fitness","volume":"229","author":"Gilchrist","year":"2004","journal-title":"J. Theor. Biol."},{"issue":"15","key":"10.1016\/j.jtbi.2015.08.032_bib17","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1073\/pnas.90.15.7381","article-title":"Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses","volume":"90","author":"Gottlinger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.jtbi.2015.08.032_bib18","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib19","first-page":"148","article-title":"Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance","volume":"8","author":"Hache","year":"2006","journal-title":"AIDS Rev."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib20","doi-asserted-by":"crossref","first-page":"e1002371","DOI":"10.1371\/journal.pcbi.1002371","article-title":"Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy","volume":"8","author":"Hosseini","year":"2012","journal-title":"PLoS Comput. Biol."},{"issue":"5","key":"10.1016\/j.jtbi.2015.08.032_bib21","doi-asserted-by":"crossref","first-page":"e63984","DOI":"10.1371\/journal.pone.0063984","article-title":"APOBEC3G-augmented stem cell therapy to modulate HIV replication","volume":"8","author":"Hosseini","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jtbi.2015.08.032_bib22","doi-asserted-by":"crossref","first-page":"e1000367","DOI":"10.1371\/journal.ppat.1000367","article-title":"Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance","volume":"5","author":"Jern","year":"2009","journal-title":"PLoS Pathog."},{"issue":"May (9)","key":"10.1016\/j.jtbi.2015.08.032_bib23","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1128\/JVI.79.9.5870-5874.2005","article-title":"Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes","volume":"79","author":"Khan","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/BF02458312","article-title":"A model for treatment strategy in the chemotherapy of AIDS","volume":"58","author":"Kirschner","year":"1996","journal-title":"Bull. Math. Biol."},{"issue":"1","key":"10.1016\/j.jtbi.2015.08.032_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cell.2008.07.032","article-title":"Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication","volume":"135","author":"Konig","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jtbi.2015.08.032_bib26","doi-asserted-by":"crossref","first-page":"a006940","DOI":"10.1101\/cshperspect.a006940","article-title":"HIV restriction factors and mechanisms of evasion","volume":"2","author":"Malim","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"6","key":"10.1016\/j.jtbi.2015.08.032_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chom.2008.04.008","article-title":"HIV-1 accessory proteins\u2014ensuring viral survival in a hostile environment","volume":"3","author":"Malim","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.jtbi.2015.08.032_bib28","doi-asserted-by":"crossref","first-page":"e1000574","DOI":"10.1371\/journal.ppat.1000574","article-title":"HIV-1 Vpu neutralizes the antiviral factor Tetherin\/BST-2 by binding it and directing its beta-trcp2-dependent degradation","volume":"5","author":"Mangeat","year":"2009","journal-title":"PLoS Pathog."},{"issue":"6944","key":"10.1016\/j.jtbi.2015.08.032_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts","volume":"424","author":"Mangeat","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jtbi.2015.08.032_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1743-422X-11-122","article-title":"Small molecules that inhibit Vif-induced degradation of APOBEC3G","volume":"11","author":"Matsui","year":"2014","journal-title":"Virol. J."},{"issue":"4","key":"10.1016\/j.jtbi.2015.08.032_bib31","doi-asserted-by":"crossref","first-page":"e1003299","DOI":"10.1371\/journal.ppat.1003299","article-title":"Vpu binds directly to tetherin and displaces it from nascent virions","volume":"9","author":"McNatt","year":"2013","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/bip.22488","article-title":"A novel peptide to disrupt the interaction of BST-2 and Vpu","volume":"102","author":"Mi","year":"2014","journal-title":"Biopolymers"},{"issue":"1","key":"10.1016\/j.jtbi.2015.08.032_bib33","doi-asserted-by":"crossref","first-page":"e1003161","DOI":"10.1371\/journal.ppat.1003161","article-title":"24 hours in the life of HIV-1 in a T cell line","volume":"9","author":"Mohammadi","year":"2013","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chom.2007.08.001","article-title":"An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein","volume":"2","author":"Neil","year":"2007","journal-title":"Cell Host Microbe"},{"issue":"7177","key":"10.1016\/j.jtbi.2015.08.032_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3934\/mbe.2004.1.267","article-title":"An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells","volume":"1","author":"Nelson","year":"2004","journal-title":"Math. Biosci. Eng."},{"issue":"6629","key":"10.1016\/j.jtbi.2015.08.032_bib37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"issue":"5255","key":"10.1016\/j.jtbi.2015.08.032_bib38","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cell.2009.08.039","article-title":"Tetherin inhibits HIV-1 release by directly tethering virions to cells","volume":"139","author":"Perez-Caballero","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jtbi.2015.08.032_bib40","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1073\/pnas.1111573109","article-title":"Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo","volume":"109","author":"Pillai","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1137\/060663945","article-title":"Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy","volume":"67","author":"Rong","year":"2007","journal-title":"SIAM J. Appl. Math."},{"key":"10.1016\/j.jtbi.2015.08.032_bib42","doi-asserted-by":"crossref","unstructured":"Rong, L., Feng, Z., Perelson, A., 2008. Mathematical modeling of HIV-1 infection and drug therapy. In: Applied Optimization, vol. 102. Springer Berlin Heidelberg, pp. 87\u2013131 (Book Section 3).","DOI":"10.1007\/978-3-540-76784-8_3"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib43","doi-asserted-by":"crossref","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"Rong","year":"2013","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jtbi.2009.06.011","article-title":"Modeling HIV persistence, the latent reservoir, and viral blips","volume":"260","author":"Rong","year":"2009","journal-title":"J. Theor. Biol."},{"issue":"10","key":"10.1016\/j.jtbi.2015.08.032_bib45","doi-asserted-by":"crossref","first-page":"e1000533","DOI":"10.1371\/journal.pcbi.1000533","article-title":"Modeling latently infected cell activation","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Comput. Biol."},{"issue":"October (2)","key":"10.1016\/j.jtbi.2015.08.032_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2004.08.006","article-title":"Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor","volume":"328","author":"Sch\u00e4fer","year":"2004","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib47","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1128\/mBio.00036-11","article-title":"HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317\/tetherin to overcome the virion release restriction","volume":"2","author":"Schmidt","year":"2011","journal-title":"mBio"},{"issue":"11","key":"10.1016\/j.jtbi.2015.08.032_bib48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/nm945","article-title":"The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif","volume":"9","author":"Sheehy","year":"2003","journal-title":"Nat. Med."},{"issue":"February (2)","key":"10.1016\/j.jtbi.2015.08.032_bib49","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1371\/journal.ppat.0030015","article-title":"Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H","volume":"3","author":"Soros","year":"2007","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.jtbi.2015.08.032_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/jtbi.2000.1076","article-title":"Modeling plasma virus concentration during primary HIV infection","volume":"203","author":"Stafford","year":"2000","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2015.08.032_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.11.026","article-title":"Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection","volume":"449","author":"Thangavelu","year":"2014","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.jtbi.2015.08.032_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/JVI.01795-10","article-title":"Serine-threonine ubiquitination mediates downregulation of BST-2\/tetherin and relief of restricted virion release by HIV-1 Vpu","volume":"85","author":"Tokarev","year":"2011","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.jtbi.2015.08.032_bib53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","article-title":"The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein","volume":"3","author":"van Damme","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"December (23)","key":"10.1016\/j.jtbi.2015.08.032_bib54","doi-asserted-by":"crossref","first-page":"13112","DOI":"10.1128\/JVI.00892-07","article-title":"7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G","volume":"81","author":"Wang","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.jtbi.2015.08.032_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2006.10.036","article-title":"Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions","volume":"360","author":"Xu","year":"2007","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.jtbi.2015.08.032_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.chom.2008.10.004","article-title":"Genome-scale RNAi screen for host factors required for HIV replication","volume":"4","author":"Zhou","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"10","key":"10.1016\/j.jtbi.2015.08.032_bib57","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1128\/JVI.06957-11","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC","volume":"86","author":"Zuo","year":"2012","journal-title":"J. Virol."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519315004373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519315004373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:28:49Z","timestamp":1748626129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519315004373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":57,"alternative-id":["S0022519315004373"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2015.08.032","relation":{},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2015.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}